
1. sci transl med. 2019 sep 18;11(510). pii: eaas9917. doi:
10.1126/scitranslmed.aas9917.

antimalarial pantothenamide metabolites target acetyl-coenzyme biosynthesis 
plasmodium falciparum.

schalkwijk j(1), allman el(2), jansen pam(3), de vries le(4), verhoef jmj(4),
jackowski s(5), botman pnm(6), beuckens-schortinghuis ca(6), koolen kmj(7),
bolscher jm(7), vos mw(7), miller k(5), reeves sa(5), pett h(4), trevitt g(8),
wittlin s(9)(10), scheurer c(9)(10), sax s(9)(10), fischli c(9)(10),
angulo-barturen i(11), jiménez-diaz mb(11), josling g(2), kooij twa(4), bonnert
r(12), campo b(12), blaauw rh(6), rutjes fpjt(13), sauerwein rw(4)(7), llinás
m(2)(14), hermkens phh(15), dechering kj(16).

author information: 
(1)department dermatology, radboud institute molecular life sciences,
radboud university medical center, nijmegen, netherlands.
joost.schalkwijk@radboudumc.nl k.dechering@tropiq.nl.
(2)department biochemistry molecular biology huck center malaria
research, pennsylvania state university, university park, pa 16802 usa.
(3)department dermatology, radboud institute molecular life sciences,
radboud university medical center, nijmegen, netherlands.
(4)department medical microbiology, radboud institute molecular life
sciences, radboud university medical center, nijmegen, netherlands.
(5)st. jude children's research hospital, memphis, tn 38105, usa.
(6)chiralix, nijmegen, netherlands.
(7)tropiq health sciences, nijmegen, netherlands.
(8)xenogesis ltd., nottingham, uk.
(9)swiss tropical public health institute, basel, switzerland.
(10)university basel, basel, switzerland.
(11)the art discovery, derio, spain.
(12)medicines malaria venture, geneva, switzerland.
(13)radboud university, nijmegen, netherlands.
(14)department chemistry, pennsylvania state university, university park, 
pa 16802 usa.
(15)hermkens pharma consultancy, oss, netherlands.
(16)tropiq health sciences, nijmegen, netherlands. joost.schalkwijk@radboudumc.nl
k.dechering@tropiq.nl.

malaria eradication critically dependent new therapeutics target
resistant plasmodium parasites block transmission disease. here, we
report pantothenamide bioisosteres active blood-stage
plasmodium falciparum parasites also blocked transmission sexual stages to
the mosquito vector. compounds resistant degradation serum
pantetheinases, showed favorable pharmacokinetic properties, cleared
parasites humanized mouse model p. falciparum infection. metabolomics
revealed coenzyme biosynthetic enzymes converted pantothenamides into
coenzyme analogs interfered parasite acetyl-coenzyme anabolism.
resistant parasites generated vitro showed mutations acetyl-coenzyme a
synthetase acyl-coenzyme synthetase 11. introduction reversion these
mutations p. falciparum using crispr-cas9 gene editing confirmed roles 
these enzymes sensitivity malaria parasites pantothenamides.
these pantothenamide compounds new mode action may potential as
drugs malaria parasites.

copyright © 2019 authors, rights reserved; exclusive licensee american
association advancement science. claim original u.s. government 
works.

doi: 10.1126/scitranslmed.aas9917 
pmid: 31534021  [indexed medline]

